

Afynia Laboratories Closes \$5M Seed Round, Proceeds to Help Revolutionize Endometriosis Care

Hamilton, February 26, 2025 – Afynia Laboratories, a biotechnology company specializing in innovative solutions for women's health, today announced the closing of a \$5 million funding round. The investment was led by Bio-Rad Laboratories, with participation from Impact America Fund, SOSV, the Capital Angel Network, and Gaingels.

The funding will be used to progress Afynia's pipeline of women's health diagnostics initially focused on endometriosis. This condition affects almost 200 million people worldwide causing chronic pelvic pain and infertility. Existing options like diagnostic surgery are invasive, expensive, and often delay diagnosis up to 10 years. Afynia has developed a microRNA-based assay called EndomiR, which utilizes novel biomarkers to detect signs of endometriosis in the blood. This can offer a less invasive, less expensive, and more accessible molecular test for endometriosis. This investment from and collaboration with Bio-Rad Laboratories will accelerate Afynia's growth and provide a long-term partner to bring EndomiR to patients around the world.

Afynia is an academic spinout from McMaster University in Hamilton, Ontario. Afynia's Founders, Drs. Foster and Wessels, have collectively spent >45 years researching women's health and they have leveraged decades of research and intellectual property to develop Afynia's pipeline and bring a diagnostic test for endometriosis to market.

"This collaboration is a major step forward in transforming how endometriosis is diagnosed and managed," said Dr. Lauren Foster, PhD, FCAHS, Co-Founder and CEO of Afynia Laboratories. "Partnering with Bio-Rad, a leader in diagnostics innovation and Life Sciences research, will allow us to expand EndomiR's reach and improve the lives of patients worldwide."

About Afynia Laboratories

Afynia Laboratories is a biotechnology company dedicated to developing innovative diagnostic solutions for women's health. With well over 50 years of collective experience in women's health, clinical medicine, and diagnostics, Afynia is committed to advancing science and improving patient outcomes.